This article is more than 5 years old. Information may no longer be current.

VIDEO: CABOSUN trial ‘changes the game’ of first-line renal cell carcinoma therapy

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

COPENHAGEN, Denmark — Results from the CABOSUN trial may be a “game changer” in the first-line treatment of metastatic renal cell carcinoma, Sumanta K. Pal, MD, a HemOnc Today Editorial Board member and medical oncologist at City of Hope Comprehensive Cancer Center, said at the European Society for Medical Oncology Congress.

The phase 2 CABOSUN trial — designed to evaluate cabozantinib (Cabometyx, Exelixis) vs. sunitinib (Sutent, Pfizer) among poor- and intermediate-risk patients with metastatic renal cell carcinoma — met its primary endpoint to significantly prolong PFS with cabozantinib treatment.

“The CABOSUN study really challenges the premise of sunitinib being the ideal treatment even in the frontline setting,” Pal said. “So, as you look at comparisons of immuno-oncology agents in combination or alone vs. sunitinib therapy, I think we’re really going to have to decide whether or not that’s the most appropriate judgement to make.”